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Abstract
It has long been assumed that the primary influences regu-
lating cardiac contractility are the extent of mechanical loading
of muscle fibers and the activity of the autonomic nervous
system. However, the vasoactive peptide endothelin, initially
found in vascular endothelium, is among the most potent posi-
tively inotropic agents yet described in mammalian myocar-
dium. In isolated adult rat ventricular cells, endothelin's action
was slow in onset but very long lasting with an EC5. of 50 pM
that approximates the reported KD of the peptide for its recep-
tor in rat heart. When the calcium activity of the buffer super-
fusing isolated single fura-2-loaded myocytes paced at 1.5 Hz
was varied from 0.1 to 0.9 mM [Ca2"L, 100 pM endothelin
increased contractile amplitude with no significant change in
diastolic or systolic [Ca2+J, thus appearing to sensitize the
myofilaments to intracellular calcium. Pertussis toxin, or prior
exposure to a f8-adrenergic agonist, reduced or abolished the
increase in myocyte contractility induced by endothelin. This
novel and potent pharmacologic action of endothelin points to
the potential importance of local, paracrine factors, perhaps
derived from microvascular endothelium or endocardium, in
the control of the contractile function of the heart. (J. Clin.
Invest. 1990. 86:1164-1171.) Key words: inotropy * (,-adren-
ergic - endothelium * fura-2 * myocardium
Introduction
Endothelial cells have been identified as the source of a num-
ber of biologically active factors that act in a paracrine fashion
to influence the behavior of both blood-borne elements and
subjacent vascular tissue (1-3). One such factor is the potent
vasoconstrictor endothelin, originally identified by Masaki
and colleagues in conditioned media from primary cultures of
porcine aortic endothelial cells (4). Their initial reports de-
scribing endothelin's positive inotropic effect (i.e., increasing
contractility) in guinea pig atria, and its action on the secretion
of atrial natriuretic peptide in primary cultures of neonatal rat
atrial myocytes (5-7) have been confirmed by several laborato-
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ries (8-15). Subsequently, high-affinity receptors for endothe-
lin have been identified by several groups in mammalian atria
and ventricles (16-21). We report here that endothelin is the
most potent positively inotropic agent we have tested in iso-
lated adult rat ventricular myocytes. This inotropic effect was
abolished by pretreatment with pertussis toxin, thus implicat-
ing a guanine nucleotide regulatory (G) protein or proteins in
the sequence of steps leading to the inotropic response.
Masaki and colleagues have now demonstrated that at least
three isoforms of endothelin are coded in the mammalian ge-
nome, all very similar structurally, but varying in the hydro-
philicity of their NH2-terminal sequences (22). These peptides
have qualitatively similar pharmacodynamic effects, although
the pharmacokinetics of their action on varying tissues could
differ. For the purpose ofthis report, "endothelin" refers to the
originally described porcine/human endothelin, now termed
"endothelin- 1."
Methods
Calcium-tolerant isolated rat ventricular myocytes were prepared
using a variation of the methods described by Haworth et al. (23) and
Cheung et al. (24). Briefly, hearts were perfused with a Krebs-Henseleit
bicarbonate buffer containing nominally 0 Ca2 , collagenase, and hyal-
uronidase (Worthington Biomedical, Malvern, PA). Ventricles were
minced and incubated in the same buffer containing trypsin and 1 mM
CaC12, and cells were released by trituration and sedimentation in 2%
BSA. The yield ofrod-shaped cells (1.5-2.0 X 106 cells/heart) in the top
layer of the cell suspension with clear cross-striations that excluded
trypan blue was routinely > 95%. The myocytes were then allowed to
attach to 12-mm glass coverslips that had been coated with collagen
(Vitrogen 100; Collagen Corp., Palo Alto, CA) for contractility mea-
surements. For measurement of intracellular Ca2 , cells were first
loaded with fura-2/AM by incubating 2 ml of cell suspension (- 5
X 10" cells/ml) with 0.1 ml of a 4.8 ,uM fura-2/AM stock solution (0.5
ml of 1 mM fura-2/AM in dry DMSO with 0.1 ml 25% (wt/wt) Plur-
onic F127 in DMSO (Molecular Probes Inc., Eugene, OR) and 4.4 ml
FCS). The cells were then washed in Hepes-buffered medium (below),
and allowed to attach to glass coverslips coated with liquid collagen
(Vitrogen, Collagen Corp.) and stored in the dark until use. The fura-2
stock solution was sonicated and stored at -70°C in aliquots for future
use. Endothelin (synthetic porcine/human endothelin- 1) was pur-
chased from Penisula Laboratories Inc. (Belmont, CA). The lyophi-
lized peptide was reconstituted in 1.0 mM acetic acid to a final con-
centration of 40 uM, aliquoted, and kept at 4°C for no longer than 2
wk. To minimize nonspecific adsorption ofthe peptide to surfaces, all
dilute solutions ofendothelin were maintained in 0.05% BSA (Fraction
V; Sigma Chemical Co., St. Louis, MO).
Contractility and intracellular Ca2" measurements. Cardiac myo-
cytes were superfused at I ml/min with medium containing 140 mM
NaCl, 4.0 mM KCl, 0.5 mM MgC12, 0.9 mM CaC12, 5.6 mM glucose,
2% FCS, 0.05% BSA, and 5 mM Hepes at 37'C, pH 7.4. The cells were
electrically stimulated with silver electrodes at 1.5 Hz with 3-ms pulses.
Light-dark contrast at the cell end provided a marker for measurement
of amplitude and velocity of cell motion. In this cell preparation, the
1164 Kelly, Eid, Kramer, O'Neill, Liang, Reers, and Smith
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/90/10/1164/08 $2.00
Volume 86, October 1990, 1164-1171
velocity of cell shortening varied linearly with contractile amplitude,
and, therefore for convenience, only the latter data are presented here.
Cell shortening and relaxation were monitored using a video motion
detector that provided new position data every 16 ms. In cells not
exposed to agonist, the absolute magnitude of shortening varied from
1-5 gm (mean 3.79±1.40 Mm; ±SD), increasing to > 10-fold in the
presence of high concentrations of external calcium or isoproterenol.
For the simultaneous measurement of contractility and [Ca2+]i, iso-
lated adult rat ventricular myocytes were loaded with the calcium-se-
lective fluorescent dye fura-2 (1-[245-carboxyoxazol-2-yl)-6-amino-
benzofuran-5-oxyl]-242'-amino-5'-methylphenoxy)ethane-N,N,N',N'-
tetraacetic acid) (Molecular Probes Inc.). Coverslips containing
attached fura-2-loaded myocytes were transferred to a circular super-
fusion chamber 1 2-mm-diam, 300 1A in volume, mounted on the stage
ofan inverted epifluorescence microscope (Nikon, Diaphot). The cov-
erslips were superfused by a peristaltic pump at a flow rate of I ml/min.
Both the chamber and superfusate were kept at 370C by a circulating
water bath. The microscope was connected to a dual excitation fluo-
rometer (Spex Industries, Inc., Edison, NJ). The excitation wave-
lengths were 340/380±1.8 nm. The emission spectrum of fura-2 at
each excitation wavelength was monitored at 500±5 nm, with a time
resolution for acquisition of ratioed data of 3 ms. To minimize pho-
tobleaching of the dye, a 50% neutral density filter was inserted in the
excitation beam path. The cells were also illuminated with light at a
wavelength above 600 nm in the phase contrast mode. An additional
postspecimen dichroic mirror deflected light at wavelengths below 450
nm to a video camera, thereby minimally affecting the emission light
from fura-2. Ventricular myocytes were loaded with 2 MM fura-2/AM
(the acetoxymethylester of fura-2) for 30 min at room temperature in
superfusion buffer. This step reduced the amplitude of contraction of
individual cells by no more than 10% at 0.9 mM Ca2+.
Because the positive inotropic response to endothelin was slow in
onset, preliminary experiments were performed to characterize the
contractile response offura-2-loaded myocytes monitored on the stage
ofan epifluorescence microscope at 370C for up to 90 min. In contrast
to our experience monitoring the behavior of isolated ventricular
myocytes in a standard phase-contrast microscope, myocyte contrac-
tility was markedly reduced in fura-2-loaded cells constantly exposed
to UV light at 340 and 380 nm. Whether this deleterious effect was
directly related to cellular toxicity due to UV light, or to a toxic metab-
olite of fura-2 as a consequence of photobleaching, is unclear. There-
fore, in protocols involving fura-2-loaded myocytes, the contractile
response ofindividual cells illuminated by a standard microscope light
source was monitored until a plateau was reached following a change
in the superfusion medium. A "snapshot" of the calcium transients
lasting < 30 s was then obtained by opening an electronic shutter, thus
minimizing the total cellular exposure to UV light to < 7 min during
an entire protocol. This toxic effect was accelerated by exposure to high
(5.4 MM) [Ca2+]J. Therefore, contractility signals are expressed as a
percentage of the baseline contractile amplitude rather than as a per-
centage of the maximum response possible for each cell.
After completion ofan experimental protocol, in situ calibration of
the fura-2 fluorescence signal was accomplished by either of two
methods: superfusion of cells with ionophores and Ca2+ calibration
buffers alone, or superfusion of myocytes with ionophores and La` to
maintain cell shape during calibration (see below). In the first method,
myocytes were initially superfused with 4 MM ionomycin in superfu-
sion buffer with 2 mM EGTA and no added calcium at pH 7.4, fol-
lowed by this same buffer containing 2 MM CCCP, pH 7.15. After the
fura-2 emission spectra had stabilized at a minimum value, the cells
were superfused with buffer containing 0.9 mM Ca2+, 4 MM ionomy-
cin, 2 MM CCCP at pH 7.15. Finally, the autofluorescence of the cell
and the contribution of partially hydrolyzed, Ca2+-insensitive fura-2
could then be determined by the addition of I mM Mn2" to quench the
fura-2 within the cell.
Many cells could not be calibrated in this fashion because of the
propensity of isolated myocytes to undergo shape changes during the
superfusion of Ca2" calibration buffers. Consequently, we developed a
calibration method that exploits the properties of lanthanum ion to
induce myofilament relaxation (25). The substitution of lanthanum
for calcium allows determination of ion-saturated fura-2 fluorescence
under conditions where both cell shape and energy status are pre-
served. Using this technique, adult myocytes were individually cali-
brated in situ by sequential exposure to calibration buffers containing
(a) the standard superfusion buffer with I mM EGTA and 5 mM
pyruvate for 30 s; (b) superfusion buffer with 10 MAM ionomycin for at
least 5 min until a stable signal was achieved; and (c) superfusion with
10 MM ionomycin and 1 mM LaC12 (no EGTA) for 2-3 min until a
stable maximum was achieved. [Ca2+]i was then determined as de-
scribed by Grynkiewicz et al. (26) with a correction for the altered ion
binding and spectral properties of fura-2 with La3+ compared to Ca".
Fura-2 displays a hypsochromic effect of 6 nm on binding La3 with
both hyperchromic (at 340 nm) and hypochromic (at 380 nm) effects,
and an affinity for La3+ that is much higher than for Ca2+ or for Mn2+;
therefore, correction factors have been derived and validated (25).
Although the sampling rate of the spectrofluorometric instrumenta-
tion used in collecting the data in this report was sufficiently rapid (a
ratioed fura-2 signal every 3 ms) to capture systolic and diastolic values
for cytosolic Ca2' reliably, no comment can be made about the rate of
decline of intracellular Ca2+ transients in control, isoproterenol or
endothelin-treated cells due to the concern that the dissociation rate of
Ca2+ from the fura-2/Ca2+ complex might limit the resolution of the
time course of the decline in cytosolic [Ca2i].
Exposure of myocytes to pertussis toxin. Freshly isolated rod-
shaped cells were suspended in Hepes-buffered medium and incubated
at 37°C with 100 ng/ml pertussis toxin for 3 h. The in vitro ADP-ribo-
sylation reaction then was performed at 37°C for 40 min as previously
described (27). Analysis of protein bands was performed on 11% acryl-
amide gels prepared according to Laemmli (28). Dried gels were ex-
posed to Kodak XAR film with enhancing screens for 1-2 d at -700C.
Autoradiographs were scanned on a laser densitometer (LKB Instru-
ments, Inc., Gaithersburg, MD). Fig. 6 depicts an autoradiogram of
SDS-PAGE of pertussis toxin-treated and control cell homogenates.
The amount of [32PJADP-ribosylation corresponded to the amount of
pertussis toxin-sensitive unreacted G protein(s) and was inversely pro-
portional to the amount ofG protein ADP-ribosylated from the endog-
enous NAD in the intact myocyte.
Results and Discussion
Endothelin and myocyte contractile amplitude. To obviate the
potential complication of diffusion limitations and the pres-
ence of cells other than myocytes that might bind and metabo-
lize the peptide in intact tissue preparations, we studied the
calcium-tolerant isolated adult rat ventricular myocyte, an ex-
perimental model that has been characterized in detail in our
laboratory. In Fig. 1, the contractile response of isolated ven-
tricular myocytes is plotted as a function of endothelin con-
centration in the bathing media. Due to a tendency for cells to
have a diminished response to higher doses ofthe peptide after
a 7-10-min exposure at a lower concentration (e.g., 0.5-10
pM), the concentration-effect curve was constructed testing
individual cells at one endothelin concentration only (n
= 6-10 cells at each point).
In this preparation, it was apparent that endothelin was the
most potent positively inotropic agent we have tested to date,
with a characteristic slow onset and long duration of action.
Although occasional cells showed a definite response between
10 and 100 fM, consistent responses were apparent only above
0.5 pM; the EC50 was 50 pM. In contrast, similar increases in
contractile amplitude (140-190% of control amplitude) were
obtained only at significantly higher doses of other agonists
(e.g., 10 nM isoproterenol, 30 nM Bay K 8644, or 100 AM
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Figure 1. Concentration-effect relationship of endothelin in isolated
adult rat ventricular myocytes. Changes in contractile amplitude in
single cardiac myocytes were measured using an optical-video system
as described in Methods. Due to a tendency for cells to have a di-
minished response to higher doses of the peptide after a 7-10-min
exposure at a lower concentration (e.g., 0.5-10 mM), the concentra-
tion-effect curve was constructed using individual cells at one con-
centration only (n = 6-10 cells at each point).
phenylephrine). Nevertheless, the average maximal response
or efficacy of endothelin at 500 pM approximated 60% of the
maximal response to 1 juM isoproterenol or high (5.4 mM)
[Ca>]0 in this model. Interestingly, the contractile response of
cells exposed to concentrations of endothelin above 10 nM
was not consistent. Approximately one-half of the cells exam-
ined had limited inotropic responses (105-150% of control),
while the remainder had an increase in contractile amplitude
of 170-250%. The reason for this variability is unclear.
After addition of endothelin to the superfusion medium,
the time to onset of an inotropic response was 4-6 min; the
mean time to reach the maximum contractile response ofa cell
over a dose range from 0.5 pM to 100 nM was 7.7±2.7 min
(mean±SD; n = 70 cells). At any endothelin concentration, the
time for a fall in inotropic response after removal of the pep-
tide from the superfusion medium was relatively long (usually
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> 8 min) with little or no change in contractile amplitude
observed in 50% of cells even at 15 min after washout. The
prolonged action of endothelin may be due either to delayed
dissociation from sarcolemmal receptors, a prolonged genera-
tion of an intracellular signal, or both. At the present time, we
have no evidence to support either mechanism.
Intracellular [Ca2"] and myocyte contractility. Since most
positively inotropic agents typically act by increasing cytosolic
calcium (29, 30), contractility and cytosolic calcium activity
([Ca2+],) were measured concurrently in isolated rat ventricu-
lar myocytes using the calcium-selective fluorescent dye
fura-2. The relationship between changes in [Ca2+]i and con-
tractile amplitude was examined either by exposing myocytes
to graded concentrations of [Ca2b]0 in the presence or absence
of endothelin or by comparing the inotropic response of myo-
cytes to endothelin with that of the f3-adrenergic agonist, iso-
proterenol.
To examine the relationship between [Ca2+1 and contrac-
tility over a range of external [Ca2+]0 in the presence and ab-
sence ofendothelin, each ventricular myocyte was subjected to
stepwise reductions in [Ca2"] from 0.9 mM to 0.1 mM, fol-
lowed by a stepwise return to 0.9 mM calcium in the presence
of 0 or 100 pM endothelin. This protocol has the virtue of
allowing paired comparisons of [Ca2+]i and contractile ampli-
tude in the same cell in the presence and absence of endothe-
lin, over a range of external [Ca2+]0. However, the use of a
descending-ascending [Ca2+]0 protocol such as this presumes
the absence of any substantial degree of hysteresis in either
[Ca2] or contractility over the range of [Ca"]0 studied. In
ventricular myocytes not loaded with fura-2 and stepped
through a similar protocol, there was no hysteresis in the con-
tractile response to calcium in the absence of endothelin (n = 7
cells). Similarly, in fura-2-loaded myocytes not exposed to en-
dothelin, there was no hysteresis in contractile amplitude be-
tween the [Ca2]0 step down and step up stages of the protocol
nor was there a significant change in the systolic [Ca2]i at any
given [Ca>2]0 in control cells, as indicated by the absence of
any significant degree of variance for systolic [Ca>1J at each
point in the control cells (Fig. 2 B, open diamonds).
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Figure 2. Endothelin enhances the contractile response to [Ca2"]. The relationship between changes in external calcium activity ([Ca2+]) and
myocyte contractile amplitude was investigated in rat ventricular myocytes, loaded with the calcium-selective fluorescent dye fura-2. Cells were
exposed initially to 0.9 mM [Ca2+] followed by stepwise reductions in [Ca2>]0 to 0.1 mM. Each cell was then exposed to medium alone or to
100 pM endothelin at 0.1 mM [Ca2+]0 and subsequently stepped back up to 0.9 mM [Ca2+]0. A and B illustrate, respectively, the contractile
amplitude and peak systolic [Ca2+]i as a percentage of their initial values at 0.9 mM [Ca2 ]k at the beginning of the protocol for three control
cells (open symbols) and three cells exposed to 100 pM endothelin during the step up phase only (solid symbols). A t test for paired observations
was used with a modified Bonferroni correction for multiple comparisons (*, P < 0.05; **, P < 0.01).
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In contrast, in those cells exposed to 100 pM endothelin
during the step up from 0.1 to 0.9 mM [Ca2+1k, there was a
marked increase in contractile amplitude even at 0.1 mM
[Ca2+]. (Fig. 2 A). At 0.1 mM [Ca2"] in the absence of the
peptide, 2 of 3 cells had stopped contracting despite continuing
stimulation pulses, but began beating 5 min after being
switched to endothelin-containing medium. Importantly, de-
spite a marked increase in contractile amplitude that averaged
234% (n = 3) of baseline at 0.9 mM Ca2" (Fig. 2 A), there was
no significant increase in the systolic Ca2+ (Fig. 2 B) or in the
diastolic [Ca2+], or time averaged [Ca2+], (data not shown).
The calcium data in Figs. 2 B and 3 A are normalized to the
systolic Ca2+ values at 0.9 mM [Ca2+]. at the beginning of the
protocol. Using La3+, both to prevent changes in cell shape and
to calibrate in situ the fura-2 signal in myocytes (see Methods
and reference 25), the systolic [Ca2+1 at 0.9mM [Ca2+J0 ranged
from 820 to 1050 nM and the diastolic [Ca2+]i ranged from 48
to 110 nM in cells paced at 1.5 Hz.
When the relationship between cytosolic calcium and con-
tractile amplitude induced by step changes in [Ca2+]J is exam-
ined, as shown in Fig. 3 A, endothelin appears to increase
myofilament responsiveness to cytosolic calcium. To deter-
mine ifthis pharmacologic response to endothelin was qualita-
tively different from that observed with another positively ino-
tropic agent, rat ventricular myocytes were exposed to either
100 pM endothelin or low concentrations of the f3-adrenergic
agonist isoproterenol that resulted in similar increases in con-
tractile amplitude. As illustrated in Fig. 3 B, although an in-
crease in systolic [Ca2+]J was observed in at least one cell in
association with a 250% increase in contractility with endoth-
elin, when compared to the response to isoproterenol, endoth-
elin exposure produced a greater increment in contractile am-
plitude for any given change in [Ca2+],. The concentration of
isoproterenol used in this study (5-50 nM) was below that
reported to induce a decrease in myofilament sensitivity to
cytosolic Ca2+ (32), but we cannot exclude such an effect on
isolated rat ventricular myocytes in our experiments. Interest-
ingly, an increase in peak systolic calcium and diastolic cal-
cium was variably seen in some isolated myocytes exposed to
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relatively high concentrations ofendothelin (> 5 nM; data not
shown).
In each of the experiments described above, after determi-
nation of the baseline [Ca2"Ji and contractile amplitude, we
routinely did not measure [Ca2+]i until there was an increase in
contractile amplitude with endothelin to prevent nonspecific
toxicity due to UV excitation light. To exclude the possibility
that there was a transient rise in [Ca2J]i in the first several
minutes following administration of endothelin, [Ca2+]J was
observed in three cells continuously for 60 s at 1-min intervals
for 10 min after addition of 100 pM endothelin. The raw data
for [Ca2+], transients (the 340/380 ratio ofthe fura-2 excitation
signal) and contractility from one representative cell are shown
in Fig. 4. In no cell was a rise in diastolic, systolic, or the
time-averaged integral of [Ca2+], transient detected, although
in each cell there was the expected rise in contractile ampli-
tude.
These observations are made on unloaded cells; that is, the
cells undergo shortening against an internal load that is pre-
sumed to be constant (isotonic), as opposed to contraction
against an external load which more closely represents condi-
tions in vivo. Nevertheless, some recent observations support
the usefulness of the isolated myocyte model in the study of
cardiac contractility. Lee and Allen, in isolated ferret papillary
muscles, have shown qualitatively similar results of several
interventions on contractile performance measured either as
isotonic muscle shortening or isometric tension development
(31). In addition, Kent et al. have recently shown that the rate
and extent of shortening of unfettered isolated feline myocytes
is analogous to the force-velocity relationship ofisolated linear
cardiac muscle (33).
The evidence presented here that endothelin enhances
myocyte contractility in the absence of substantial changes in
time averaged [Ca2+]i or in the cystolic [Ca2+]i transient is of
interest in relation to recent observations on the mechanism of
action of a-adrenergic agonists (33, 34). In intact aequorin-
loaded rabbit papillary muscles (34) and in the hyperperme-
able rat ventricular strip preparations (35, 36), a-adrenergic
agonists have been reported to increase contractility by two
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Figure 3. Endothelin enhances the contractile response to [Ca2+]j. (A) The values for contractile amplitude and peak systolic [Ca2+]i in 6 cells at
the beginning of the protocol described in Fig. 2 were assigned a value of 100%, and the relative contractility and systolic [Ca2+]i responses for
each cell are shown for the subsequent descending and ascending steps of the protocol for control cells (open circles), and for cells exposed to
100 pM endothelin during the ascending limb only (solid symbols). (B) Fura-2-loaded ventricular myocytes were exposed to either 100 pM en-
dothelin or a concentration of sufficient isoproterenol (5-50 nM) to yield a roughly equivalent increase in contractile amplitude. The data are
expressed as a percentage of contractile amplitude and systolic calcium above predrug control values at 0.9 mM [Ca2"] for eight endothelin-ex-
posed cells (solid symbols) or 10 isoproterenol-exposed cells (open symbols).
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mechanisms: (a) enhancing myofilament sensitivity to cal-
cium, probably by increasing the affinity of troponin C for
Ca2+; and (b) by increasing the cytosolic [Ca2+] transient, al-
though to a lesser extent than is observed with j3-adrenergic
agonists for a comparable increase in contractile force.
The positive inotropic effect of endothelin was diminished
by organic inhibitors of voltage-sensitive, L-type sarcolemmal
calcium channels, including verapamil and nifedipine. As
shown in Fig. 5, verapamil had the expected negative inotropic
effect in control cells, with an IC50 of - 0.5 MM. Verapamil
also decreased the absolute magnitude of inotropic response to
endothelin. However, it is of interest that the relative fall in
contractile amplitude in cells treated with 100 pM endothelin
(- 33% at 1 MM verapamil) was less than that seen in control
cells (- a 60% decline at 1 uM). This suggests that the response
to endothelin is relatively unaffected by or resistant to reduced
Ca2+ conductance through sarcolemmal L-type channels, and
is consistent with the hypothesis that endothelin may be in-
creasing contractile amplitude by a novel mechanism, perhaps
by increasing contractile element sensitivity to intracellular
calcium. It is also possible that endothelin indirectly affected
verapamil's binding to or action at sarcolemmal L-channels by
use-dependent blockade, perhaps due to membrane hyperpo-
larization, although this seems less likely.
Pertussis toxin and the inotropic response to endothelin. As
GTP binding proteins have been shown to be important inter-
mediates in the transduction of many signals at the cell mem-
brane, including those that initiate phosphatidylinositol hy-
drolysis and Ca2" mobilization, we tested whether pertussis
toxin-sensitive G proteins might be involved in the sequence
ofevents after endothelin-receptor binding (37). The relatively
prolonged time to onset of the positive inotropic effect of en-
dothelin was also of interest in view of recent evidence from
several laboratories that endothelin rapidly induces phospha-
tidylinositol hydrolysis or activation of phospholipase A2 in a
number of tissues, including rat atrium (13, 39-41a). There-
fore, we also determined whether early pharmacologic effects
ofthe peptide, possibly mediated by pertussis toxin-sensitive G
proteins, could be unmasked during the 4- to 5-min lag phase
preceding the positive inotropic effect of the peptide.
Preincubation of freshly dissociated intact rat ventricular
myocytes with pertussis toxin resulted in nearly complete abo-
lition of subsequent pertussis toxin-induced [32P]ADP-
ribosylation in membranes derived from these pretreated cells
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(Fig. 6), as judged by the reduced intensity of 41 and 39 kD
phosphopeptide bands in treated cells consistent with the
known molecular masses of the Gia and G~a subunits (42). In
contrast to results seen with 100 pM endothelin in nonper-
tussis toxin-treated cells, the peptide's positive inotropic effect
was either abolished or markedly reduced (108.1±13.4% of
control amplitude, n = 9) at 8 min, the usual length of time to
peak effect (Fig. 7). In addition, 6 of 9 pertussis toxin-treated
cells exhibited a transient negative inotropic response at 1-2
min after exposure to endothelin (-26.2±6.0%), and in three
pertussis intoxicated cells, the contractile amplitude dropped
below baseline within 1 min of exposure and remained there
for the duration of the protocol. Pertussis toxin pretreatment
alone did not alter the normal morphology ofthe cells, nor did
it alter their response to electrical stimulation, even after
10-15 min of pacing at 1.5 Hz. Because rapid effects of the ,B
protomers of pertussis toxin have been described in several cell
types, unrelated to ADP-ribosylation of Gia or Goa, cells pre-
treated with 100 ng/ml pertussis toxin for 1 min only were
examined as a control (43). There was no evidence for any
PERTUSIS CONTROL
TOXIN TREATED /
Figure 6. Pertussis toxin ADP-
ribosylates 41 and 39 kD G
proteins in rat ventricular
myocytes. Pertussis toxin (100
ng/ml) diminished subsequent
in vitro [32PJADP-ribosylation
_by 98%, as judged by densi-
tometry of these and other gels
(see Methods). The broad
kD band present at 39-40 kDa
likely represented both a., and
a, species in the rat myocar-
,"4 1 dium (42). These data indicate
that virtually all of the per-
tussis toxin-sensitive G,, spe-
cies were ADP-ribosylated by
endogenous NAD+ during ex-
posure of intact myocytes to
pertussis toxin.
Figure 5. Verapamil and the contractile response to
endothelin. Isolated rat ventricular myocytes were
treated with either 100 pM endothelin (solid bars; n
= 3) or superfusion buffer alone (open bars; n = 3)
for 10 min at 370C. The increase in contractile am-
plitude in the three endothelin-treated cells was
169±3.2% (mean±SD). Each cell was subsequently
exposed to increasing concentrations of verapamil,
from I nM to 10 gM, as illustrated. Verapamil de-
creased contractile amplitude in both control and
treated cells, with an IC50 of 0.5 ,uM; however, the
relative decline in endothelin-treated cells appears to
be less than in control cells.
non-G protein-related rapid effects of pertussis toxin in the
response of rat cardiac myocytes to endothelin.
As an additional control, isolated ventricular myocytes
were incubated in the presence or absence of 100 ng/ml per-
tussis toxin for 3 h at 37°C in Hepes-buffered medium, and
then exposed to 10 nM isoproterenol. Pertussis toxin pretreat-
ment increased the rise in contractile amplitude with isopro-
terenol to 400% of control (n = 2) compared to 150% of con-
trol (n = 2) in nonpertussis toxin-pretreated cells, as expected
in response to a ,B agonist after pertussis toxin. Also, although
the time course of the rise in contractile amplitude was de-
layed, pertussis toxin had no effect on the maximal increase in
contractile amplitude to either 10 gM phenylephrine or 100
nM angiotensin in similarly treated isolated myocytes.
The unmasking of an early negative inotropic effect of en-
dothelin in many cells by pertussis toxin, with the subsequent
abolition or marked diminution of the positive inotropic ac-
tion of the peptide, suggests a complex signal transduction
mechanism. The negative inotropic effect could be mediated
by protein kinase C, since we have observed a decrease in
contractility in response to phorbol ester exposure in primary
cultures of embryonic chick cardiocytes (44). An additional,
surprising observation was the effect of prior exposure of rat
ventricular myocytes to isoproterenol on their subsequent
contractile responsiveness to endothelin. Exposure of myo-
cytes to low concentrations (10-100 nM) of isoproterenol for
30-40 s resulted in a mean 2.6-fold increase in contractile
amplitude, followed by a return to baseline contractility after a
5-min washout. After this brief isoproterenol exposure, the
Figure 7. Pertussis toxin
abolishes the contractile
response to endothelin.
Isolated rat ventricular
*{_+ P myocytes were exposed
to 100 pM endothelin
either after a 3-h prein-
nS cubation in 100 ng/ml
-2 0 2 4 6 U 10 pertussis toxin (open
rime [min]
circles; n = 9) or prein-
cubation at 37°C in control media (solid circles; n = 5), and the
change in contractile amplitude was recorded.
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contractile response to 100 pM endothelin was completely
abolished in six of seven cells. In four of these seven cells,
contractility initially declined upon exposure to endothelin,
returning to baseline or slightly above only after 10 min of
exposure to the peptide. This indicates that ,3 agonists can
modify cellular responsiveness to endothelin's action, perhaps
by partially uncoupling the activated receptor from a signal
transducing G protein. jB agonists could also affect another step
or steps downstream in the signal transduction cascade, as they
are known to desensitize myofilament responsiveness to cyto-
solic Ca2", due at least in part to phosphorylation oftroponin I
in response to increased cAMP levels. This explanation is the
more intriguing possibility given our data supporting endothe-
lin's action enhancing myofilament sensitivity to calcium.
These observations indicate that endothelin is among the
most potent inotropic substances for mammalian myocar-
dium yet described, with a mechanism of action qualitatively
different from many other endogenous agents and drugs that
increase cardiac contractility. The EC50 of endothelin in iso-
lated ventricular myocytes is at or below 50 pM, in accord with
binding affinities for the cardiac sarcolemmal endothelin re-
ceptor determined in either intact tissue or sarcolemmal
membranes (16-21). The onset of endothelin's action is slow
while its duration is prolonged, indicating that the peptide, if it
acts as an endogenous regulator of myocardial contractility in
vivo, may modulate the inotropic responsiveness of the myo-
cardium over a timeframe of minutes to hours, possibly by
sensitizing the myofilaments to changes in cytosolic calcium
induced by the more rapid, but shorter-lived effects of neuro-
humoral factors. Although an increase in cytosolic calcium in
single isolated ventricular cells has been documented at en-
dothelin concentrations of20 nM (45), we did not observe any
consistent increase in systolic or diastolic calcium at concen-
trations below 1 nM.
An alternative explanation for our failure to witness an
increase in intracellular Ca2", aside from the lower concentra-
tion of endothelin used here, is our choice of species. The
increase in cytosolic Ca2" noted in rabbit myocytes (45) was
accompanied by an increase in action potential duration to
470 ms. The rat action potential is, by contrast, much abbre-
viated. Although we did not measure action potential dura-
tion, other qualitative differences in the force-frequency rela-
tionship between the rat and other mammalian species point
to important differences in intracellular Ca2' homeostasis (46)
that could explain the absence of a rise in cytosolic Ca2" with
endothelin in the rat but not in the rabbit and, perhaps, other
species. Regardless, at the stimulation frequency used here, 1.5
Hz, the absence ofany detectable rise in cytosolic Ca2+ implies
that some sensitization of the contractile apparatus to Ca2+
occurred, an effect that might be apparent, to a greater or lesser
degree, in other species.
Our findings suggest that the microvascular and/or endo-
cardial endothelium of the heart, if it is the relevant source of
the peptide in myocardium, and is analogous to the role de-
scribed for endothelium in conduit and resistance vessels, may
play a role in the modulation of cardiac contractile state, per-
haps in response to changes in microvascular blood flow. Also,
recent reports that the endocardial endothelium appears to
modulate the inotropic response to changes in [Ca2+]o in papil-
lary muscle (47, 48) are consistent with our observations that
an endothelium-derived factor increases the contractile re-
sponsiveness to calcium. Irrespective of the mechanism, en-
dothelin may be one of a number of endogenous autacoids
released by microvascular or endocardial endothelium, and
transported vectorially to subjacent cardiac myocytes, that can
act to regulate cardiac function.
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